Orteronel
From Wikipedia, the free encyclopedia
| Orteronel | |
|---|---|
 | |
| IUPAC name 6-(7-Hydroxy-6,7-dihydro-5H-pyrrolo[1,2-c]imidazol-7-yl)-N-methylnaphthalene-2-carboxamide | |
| Other names TAK-700 | |
| Identifiers | |
| CAS number | 566939-85-3  |
| PubChem | 9883029 |
| ChemSpider | 8058704 |
| UNII | UE5K2FNS92 |
| KEGG | D10146 |
| ChEMBL | CHEMBL1921976 |
| Jmol-3D images | Image 1 |
| |
| |
| Properties | |
| Molecular formula | C18H17N3O2 |
| Molar mass | 307.35 g mol−1 |
| Except where noted otherwise, data are given for materials in their standard state (at 25 °C (77 °F), 100 kPa) | |
| Infobox references | |
Orteronel (TAK-700) is an experimental drug for the treatment of cancer discovered by Takeda Pharmaceutical Company and under development by Millennium Pharmaceuticals.[1] It is currently in Phase III clinical trials for metastatic, hormone-refractory prostate cancer.[2]
Orteronel is an androgen synthesis inhibitor. It selectively inhibits the enzyme CYP17A1[3] which is expressed in testicular, adrenal, and prostatic tumor tissues. CYP17 catalyzes two sequential reactions: (a) the conversion of pregnenolone and progesterone to their 17-α-hydroxy derivatives by its 17 α-hydroxylase activity, and (b) the subsequent formation of dehydroepiandrosterone (DHEA) and androstenedione, respectively, by its C17,20 lyase activity.[4] DHEA and androstenedione are androgens and precursors of testosterone. Inhibition of CYP17 activity thus decreases circulating levels of testosterone.
References
- ↑ Millennium and Takeda Announce Advancement of Prostate Cancer Program, Millennium Pharmaceuticals
- ↑ TAK-700, ClinicalTrials.gov
- ↑ Yamaoka, M; Hara, T; Hitaka, T; Kaku, T; Takeuchi, T; Takahashi, J; Asahi, S; Miki, H et al. (2012). "Orteronel (TAK-700), a novel non-steroidal 17,20-lyase inhibitor: Effects on steroid synthesis in human and monkey adrenal cells and serum steroid levels in cynomolgus monkeys". The Journal of steroid biochemistry and molecular biology 129 (3–5): 115–28. doi:10.1016/j.jsbmb.2012.01.001. PMID 22249003.
- ↑ Attard G, Belldegrun AS, de Bono JS (December 2005). "Selective blockade of androgenic steroid synthesis by novel lyase inhibitors as a therapeutic strategy for treating metastatic prostate cancer". BJU Int. 96 (9): 1241–6. doi:10.1111/j.1464-410X.2005.05821.x. PMID 16287438.
| ||||||||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||||
This article is issued from Wikipedia. The text is available under the Creative Commons Attribution/Share Alike; additional terms may apply for the media files.